Byline: Health & Science Desk
Dateline: May 12, 2026
For all the promise of multi-cancer early detection (MCED) tests like Galleri, one number stops most people cold: $949. That is the out-of-pocket cost for the leading MCED test on the market today — a price tag that puts cutting-edge cancer screening out of reach for millions.
But researchers at the University of California, Los Angeles (UCLA) have developed an alternative that could shatter that barrier. It is called MethylScan, and its estimated lab cost is less than $20 per sample.
The big question: Can a test that costs 47 times less than its competitors actually work?
Here is what the data shows — and why MethylScan is not yet available to you.
What Is MethylScan?
MethylScan is a blood-based cancer detection test that identifies abnormal DNA methylation patterns — chemical “tags” on DNA that control gene expression. Cancerous tumors shed fragments of their DNA into the bloodstream (called cell-free DNA, or cfDNA), and these fragments carry unique methylation signatures.
How it differs from expensive MCED tests:
| Galleri (GRAIL) | MethylScan (UCLA) | |
|---|---|---|
| Method | Deep whole-genome methylation sequencing | Targeted methylation analysis |
| Computational cost | High (requires massive data processing) | Low (focused panel) |
| Estimated lab cost | ~500–500–700 (sold at $949 to consumer) | < $20 |
| Cancer types covered | 50+ | 4 (in published studies) |
The key innovation is simplicity. Instead of scanning the entire genome for methylation signals — which requires expensive sequencing and powerful computers — MethylScan focuses only on the most informative methylation markers. This “targeted” approach dramatically reduces cost without eliminating detection capability.
The Numbers: How Well Does It Work?
In published research, MethylScan was evaluated across four cancer types:
- Liver cancer
- Lung cancer
- Ovarian cancer
- Stomach cancer
Performance metrics:
| Metric | MethylScan Result | What This Means |
|---|---|---|
| Sensitivity | 63% | Detected 63 of every 100 cancers present |
| Specificity | 98% | Correctly identified 98 of every 100 healthy people as cancer-free |
Putting 63% Sensitivity in Context
Is 63% good? It depends on the use case.
- For population screening: 63% means the test would miss 37% of cancers. That is too low for a standalone “rule-out” test. However, no MCED test catches everything — Galleri’s overall sensitivity in real-world studies ranges from 51% to 67% depending on cancer stage and type.
- For triage or high-risk monitoring: 63% could be valuable as a low-cost, frequent screening tool — for example, testing high-risk patients every 6 months for a fraction of the cost of annual Galleri.
📌 Important: The 63% figure comes from studies on four cancer types. Broader validation is still needed.
The Specificity Advantage: 98% Is Solid
A 98% specificity means that for every 100 healthy people tested, 2 will receive a false positive — a “cancer signal detected” result when no cancer exists.
False positives are a major concern in MCED testing because they lead to:
- Follow-up imaging (CT scans, MRIs)
- Potentially invasive biopsies
- Patient anxiety and unnecessary medical costs
Comparison of specificity across MCED tests:
| Test | Specificity | False Positive Rate |
|---|---|---|
| Galleri | ~99.5% | 0.5% |
| MethylScan | 98% | 2% |
| Conventional mammography | ~92-96% | 4-8% |
At 98%, MethylScan’s false positive rate is higher than Galleri’s but still better than many standard single-cancer screenings. For a $20 test, this is considered highly competitive.
Why Isn’t MethylScan Available to Consumers?
Status: Research phase only. Not FDA approved. Not for sale.
To become a real product, MethylScan must clear several hurdles:
1. Larger Clinical Validation
The published studies are promising but small. MethylScan needs validation in trials with thousands of participants across diverse populations and multiple clinical sites.
2. Expansion of Cancer Types
Four cancers is a start, but a truly useful MCED test should cover more — particularly aggressive cancers like pancreatic, esophageal, and colorectal, for which early detection saves lives.
3. Commercial Partnership
UCLA is a research institution, not a diagnostics company. MethylScan would likely need to be licensed to or acquired by a commercial entity (like Quest Diagnostics, LabCorp, or a biotech startup) to scale production, conduct FDA trials, and distribute the test.
4. FDA Pathway
As a laboratory-developed test (LDT), MethylScan could potentially be offered under the FDA’s new LDT regulations without full premarket approval — but it would still require analytical validation and a CLIA-certified lab. The safest route would be a De Novo classification or Premarket Approval (PMA) , which takes years and millions of dollars.
MethylScan vs. Galleri: A Side-by-Side Comparison
| Feature | MethylScan (UCLA) | Galleri (GRAIL) |
|---|---|---|
| Lab cost | ~$20 | ~$500-700 |
| Consumer price | N/A (not sold) | $949 |
| FDA status | Research only | PMA submitted (not approved) |
| Cancer types covered | 4 (liver, lung, ovary, stomach) | 50+ |
| Sensitivity | 63% (across 4 types) | ~51-67% (depending on stage) |
| Specificity | 98% | ~99.5% |
| Available now? | ❌ No | ✅ Yes (as LDT) |
| Insurance coverage | N/A | ❌ No (out-of-pocket only) |
What MethylScan Tells Us About the Future of MCED
MethylScan is not a product — yet. But it is a proof of concept that low-cost population-scale cancer screening is technically feasible.
Here is what the research signals:
✅ The Good
- Cost can drop dramatically without completely sacrificing accuracy.
- Targeted methylation panels may be sufficient for high-prevalence cancers.
- A $20 test could be deployed annually in primary care or even in low-resource settings (rural clinics, developing countries).
⚠️ The Challenges
- Broader cancer coverage requires more methylation markers, which increases cost.
- Sensitivity must improve to reduce missed cancers.
- False positives (2%) could overwhelm healthcare systems if millions are tested.
Realistic Timeline: When Might MethylScan Become Available?
| Phase | Estimated Timeline | Status |
|---|---|---|
| Initial research publication | 2023–2025 | ✅ Complete |
| Larger validation trials | 2026–2028 | 🔄 In progress (assumed) |
| Commercial licensing | 2027–2029 | ⏳ Pending |
| FDA submission | 2029–2030 | ⏳ Pending |
| Potential availability | 2030–2032 | 🎯 Earliest realistic target |
Bottom line: Do not expect to order MethylScan next year. But watch for news about licensing or expanded trials — that is when it becomes real.
Should You Wait for MethylScan Instead of Buying Galleri?
No. If you are at high risk for cancer (family history, genetic mutation, known risk factors), existing MCED tests like Galleri — despite the $949 price — are available now and cover far more cancer types.
But… if you are a healthcare system administrator, researcher, or public health official, MethylScan represents the holy grail: affordable, repeatable, population-wide screening.
For the average person, the takeaway is this:
MethylScan proves cheap MCED is possible. It does not yet prove cheap MCED is ready.
References
- UCLA Jonsson Comprehensive Cancer Center – MethylScan research summary (2025–2026)
- GRAIL, Inc. – Galleri clinical study data (PATHFINDER 2, 2025)
- Nature / Cancer Discovery – Targeted methylation for low-cost cancer detection (relevant literature)
- FDA – Breakthrough Device and Premarket Approval pathways
| Criterion | Rating |
|---|---|
| Scientific promise | ⭐⭐⭐⭐ (4/5) – Solid proof of concept |
| Clinical readiness | ⭐ (1/5) – Research only |
| Cost advantage | ⭐⭐⭐⭐⭐ (5/5) – Game-changing if validated |
| Availability | ⭐ (1/5) – Not for sale |
| Overall | Promising but prematur |
A significant barrier to MCED adoption is cost. In response, researchers at UCLA have developed a test called MethylScan. By focusing on methylation patterns without requiring the deep (and expensive) sequencing that Galleri requires, researchers estimate the workflow cost could be less than $20 per sample.
Performance: In studies, MethylScan showed 63% sensitivity across four cancer types at 98% specificity.
Status: Still in research phases. It highlights where the market is headed: cheaper, accessible population screening, but it is not yet a commercial product available to consumers.”
The Cost Barrier: Enter MethylScan
A significant barrier to MCED adoption is cost. At $949 out-of-pocket, Galleri is simply unaffordable for routine annual screening for most people. Insurance does not cover it. Medicare does not cover it. And that price tag puts early detection out of reach for exactly the populations that might benefit most: those without premium health plans or disposable income.
In response, researchers at the University of California, Los Angeles (UCLA) have developed an experimental alternative called MethylScan.
How it works: Like Galleri, MethylScan looks for DNA methylation patterns — chemical “tags” on DNA that change when cancer is present. But instead of scanning the entire genome (which requires deep, expensive sequencing and powerful computers), MethylScan uses a targeted approach, focusing only on the most informative methylation markers.
The cost advantage: Because it requires less sequencing and less computational power, researchers estimate the lab workflow cost could be less than $20 per sample — roughly 1/47th the cost of Galleri’s underlying lab work.
The performance trade-off (so far):
| Metric | MethylScan Result | What It Means |
|---|---|---|
| Sensitivity | 63% | Catches about 63 of every 100 cancers (of the four types studied) |
| Specificity | 98% | 2 out of 100 healthy people would receive a false positive |
To put that in perspective: Galleri’s overall sensitivity in real-world studies ranges from approximately 51% to 67% depending on cancer stage, with specificity around 99.5%. MethylScan’s 63% sensitivity is comparable to Galleri for the specific cancer types tested. Its 98% specificity is slightly lower — meaning slightly more false alarms — but still better than many conventional single-cancer screenings like mammography.
The catch: MethylScan has only been studied across four cancer types (liver, lung, ovary, and stomach). Galleri covers more than 50. And MethylScan remains strictly in the research phase — it is not FDA approved, not commercially available, and cannot be ordered by patients or doctors today.
Why it still matters: MethylScan is not a product. It is a proof of concept. It demonstrates that low-cost, population-scale MCED screening is technically feasible. If validated in larger trials and expanded to more cancer types, a $20 test could transform cancer screening — imagine adding it to routine annual blood work for the same cost as a cholesterol panel.
FAQ 1: Can a methylation test detect cancer?
Short answer: Yes.
Methylation tests detect cancer by analyzing DNA methylation patterns — chemical “tags” on DNA that control gene expression. When cancer develops, these patterns change abnormally. Tumor cells shed fragments of their DNA into the bloodstream (called cell-free DNA or cfDNA), and methylation tests scan these fragments for cancer-specific signatures.
How MethylScan does it:
MethylScan uses a targeted methylation approach, focusing only on the most informative markers rather than scanning the entire genome. In published studies, it detected 63% of cancers across four types (liver, lung, ovary, stomach) with 98% specificity.
Limitations:
No methylation test is perfect. MethylScan misses about 37% of cancers (false negatives) and produces false positives for 2% of healthy individuals. It is also currently limited to four cancer types.
Bottom line: Methylation tests are a proven and promising method for multi-cancer detection, but they are not yet a replacement for standard screenings or a definitive diagnostic tool.
FAQ 2: Is a Galleri cancer test worth it?
Short answer: It depends on your risk profile, budget, and expectations.
What Galleri offers:
- Detects 50+ cancer types from a single blood draw
- Specificity of ~99.5% (very few false positives)
- Available now (no FDA approval yet, but offered as a lab-developed test)
- Cost: $949 out-of-pocket (insurance does not cover it)
What Galleri does NOT do:
- It is not FDA approved (PMA application submitted January 2026)
- It does not replace standard screenings (mammograms, colonoscopies, Pap smears)
- It can miss cancers (sensitivity ranges from ~51% to 67% depending on stage)
Who might find it worth it:
- Individuals with strong family history of cancer
- Known genetic mutations (BRCA, Lynch syndrome, etc.)
- People willing to pay $949 for peace of mind despite limitations
Who might skip it:
- Average-risk individuals without symptoms
- Those who cannot afford $949 out-of-pocket
- Anyone expecting a perfect test (it is not)
Comparison to MethylScan:
| Galleri | MethylScan | |
|---|---|---|
| Cost | $949 | ~$20 (research only) |
| Cancer types | 50+ | 4 (currently) |
| Availability | Now | Years away |
| FDA status | PMA submitted | Research only |
Bottom line: Galleri is the best available MCED test for those who can afford it and understand its limitations. MethylScan is a promising future alternative — but not an option today.
FAQ 3: What does a methylation blood test do?
Short answer: A methylation blood test analyzes chemical patterns on DNA to detect abnormalities associated with cancer, aging, and other diseases.
How it works step by step:
- Blood draw – A small sample of blood is taken.
- DNA extraction – Cell-free DNA (cfDNA) is isolated from the blood.
- Methylation analysis – The test scans DNA fragments for abnormal methylation patterns that are characteristic of cancer cells.
- Signal interpretation – A machine-learning algorithm determines whether a “cancer signal” is present and, in some tests (like Galleri), predicts the likely tissue of origin.
What MethylScan specifically does:
Unlike whole-genome tests (Galleri), MethylScan uses a targeted approach — it looks only at specific methylation markers known to be informative for four cancer types (liver, lung, ovary, stomach). This keeps costs low (~$20 per sample) but limits the breadth of detection.
What methylation tests CANNOT do:
- Diagnose cancer definitively (positive results require follow-up imaging/biopsy)
- Detect all cancers (sensitivity varies)
- Replace routine screenings
Other uses of methylation testing:
Beyond cancer detection, methylation blood tests are also used for:
- Biological age estimation (“epigenetic clocks”)
- Early detection of specific cancers (e.g., colorectal cancer with Cologuard)
- Monitoring treatment response in cancer patients
Bottom line: A methylation blood test is a powerful screening tool that looks for cancer “signals” in your DNA — but a positive result is a starting point for investigation, not a final diagnosis.
FAQ 4: Is a methylation test really worth it?
Short answer: For cancer screening today — possibly, but with caveats. For the future — almost certainly.
Worth it for whom?
| Scenario | Is it worth it? | Why |
|---|---|---|
| High-risk individual (family history, genetic mutation) | ✅ Yes | Early detection could save your life; Galleri is the current best option |
| Average-risk, asymptomatic | 🤔 Maybe | Benefit is unproven; $949 is steep; false positives can cause harm |
| Someone who cannot afford $949 | ❌ No (today) | MethylScan is not available; wait for cheaper alternatives |
| Researcher or health system planner | ✅ Yes (watching MethylScan) | $20 tests could transform population screening |
The cost-benefit analysis for Galleri (today):
- Cost: $949 per test
- Benefit: Potential early detection of 50+ cancers, but misses ~40%
- Risk: False positives leading to unnecessary procedures and anxiety
- Verdict: Reasonable for high-risk individuals; questionable for general population
The promise of MethylScan (future):
- Cost: ~$20 per test
- Benefit: Could be deployed annually in primary care for everyone
- Risk: 2% false positive rate (manageable if confirmed with follow-up)
- Verdict: Game-changing — if validated and expanded to more cancer types
What you should do today:
- Do not skip standard screenings (mammograms, colonoscopies, Pap smears).
- If you are high-risk and can afford $949, discuss Galleri with your doctor.
- Watch for news on MethylScan — but do not wait for it if you need screening now.
Bottom line: Methylation tests are worth it in principle — early cancer detection saves lives. But the “worth” depends entirely on cost, accuracy, and availability. Galleri is expensive but available. MethylScan is cheap but years away. Choose accordingly.
Bonus: Quick Reference Table
| Question | One-Sentence Answer |
|---|---|
| Can a methylation test detect cancer? | Yes — it detects abnormal DNA methylation patterns shed by tumors into the bloodstream. |
| Is Galleri worth it? | For high-risk individuals who can afford $949 — possibly; for average-risk — probably not yet. |
| What does a methylation blood test do? | It analyzes chemical tags on DNA to identify cancer signals, aging markers, or disease abnormalities. |
| Is a methylation test really worth it? | Today, for some; in the future (with $20 tests like MethylScan), for nearly everyone. |
The bottom line for consumers: Do not look for MethylScan at your doctor’s office. It is years away from commercial availability. But watch this space. If UCLA or a commercial partner successfully scales this technology, it could finally deliver what the MCED field has promised: universal, affordable, early cancer detection for everyone, not just those who can afford $949
